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Key points
 The contractile properties of human fetal cardiac muscle have not been previously studied.
 Small-scale approaches such as isolated myofibril and isolated contractile protein
biomechanical assays allow study of activation and relaxation kinetics of human fetal cardiac
muscle under well-controlled conditions.
 We have examined the contractile properties of human fetal cardiac myofibrils and myosin
across gestational age 59–134 days.
 Human fetal cardiac myofibrils have low force and slow kinetics of activation and relaxation
that increase during the time period studied, and kinetic changes may result from structural
maturation and changes in protein isoform expression.
 Understanding the time course of human fetal cardiac muscle structure and contractile
maturation can provide a framework to study development of contractile dysfunction with
disease and evaluate the maturation state of cultured stem cell-derived cardiomyocytes.
Abstract Little is known about the contractile properties of human fetal cardiac muscle during
development. Understanding these contractile properties, and how they change throughout
development, can provide valuable insight into human heart development, and provide a
framework to study the early stages of cardiac diseases that develop in utero. We characterized the
contractile properties of isolated human fetal cardiac myofibrils across 8–19 weeks of gestation.
Mechanical measurements revealed that in early stages of gestation there is low specific force
and slow rates of force development and relaxation, with increases in force and the rates of
activation and relaxation as gestation progresses. The duration and slope of the initial, slow phase
of relaxation, related to myosin detachment and thin filament deactivation rates, decreased with
gestation age. F-actin sliding on human fetal cardiac myosin-coated surfaces slowed significantly
from 108 to 130 days of gestation. Electron micrographs showed human fetal muscle myofibrils
elongate and widen with age, but features such as the M-line and Z-band are apparent even as early
as day 52. Protein isoform analysis revealed that β-myosin is predominantly expressed even at the
earliest time point studied, but there is a progressive increase in expression of cardiac troponin I
(TnI), with a concurrent decrease in slow skeletal TnI. Together, our results suggest that cardiac
myofibril force production and kinetics of activation and relaxation change significantly with
gestation age and are influenced by the structural maturation of the sarcomere and changes in
contractile filament protein isoforms.
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Introduction
The contractile properties of human fetal cardiac muscle
have not yet been described and functional information
has been primarily obtained via studies in vivo with
echocardiography. Most of what is known about the
contractile properties of developing mammalian cardiac
muscle comes from experiments in animal models.
However, these studies are limited in their applicability
to human cardiac development because of differences in
the temporal pattern and the composition of contractile
protein isoform expression.
As the human fetal heart ages, the longitudinal
shortening (ratio of atrioventricular plane displacement to
left ventricular length) decreases (Elmstedt et al. 2012) and
the left ventricle end diastolic volume increases (Luewan
et al. 2014; Brooks et al. 2014). Heart rate decreases as the
fetus grows, while diastolic filling and atrial contraction
durations, and the peak velocities of the septum, atrial
contraction and ventricle ejection all increase (Elmstedt
et al. 2013). However, conclusions from these studies are
limited by a lack of ex vivo quantitative muscle contra-
ctile studies, and thus cannot decouple the effects of Ca2+
handling and whole cell maturation from the function of
the myofilament proteins. It is unknown if the changes in
gross contraction of the heart are a result of protein iso-
form expression pattern changes, structural development
or changes to the Ca2+ handling apparatus.
Ex vivo studies on human fetal heart tissue report
significant changes in morphology, ultrastructure and
protein composition as the fetus develops. The gross
morphology of the heart undergoes considerable change
through the first 112 days of development, including
septation (separating the left and right halves between
35 and 53 days of gestation), formation of the valve
components between 49 and 56 days, and delamination
of the leaflets into the tricuspid valve between 56 and
112 days (Lamers et al. 1995). At 119 days, there are few
myofibrils in the heart and they are scattered, very short,
with thick z-bands and are loosely packed (Kim et al. 1992);
however, there is no information on the ultrastructure of
cardiomyocytes before this time point. Previous studies
have shown that several key contractile protein isoforms
change in expression levels between 49 days and full-term
gestation. The human fetal heart ventricle shows a marked
decrease in the small amount of α-myosin heavy chain
(α-MHC) between 47 and 110 days of gestation (Reiser
et al. 2001). Moreover, slow skeletal troponin I (ssTnI) is
the predominant TnI isoform expressed in the heart from
as early as 63 days of gestation to 12 weeks after birth (Sasse
et al. 1993). The continued expression of ssTnI may lead
to slower overall ATPase activity (Anderson et al. 1991;
Purcell et al. 1999).
The contractile properties of the developing human
fetal heart probably change over time due to this complex
combination of protein isoform expression changes and
the structural maturation of sarcomeres. An in-depth
study of the function of the developing myocardium is
needed to better understand the developmental process of
the heart and create better informed hypotheses regarding
the dysfunction that occurs in disease development from
structural abnormalities or genetic mutations within the
heart. Knowledge of the contractile properties of human
fetal cardiac muscle could also help to identify potential
avenues for early intervention into cardiac muscle diseases
that develop in utero.
Here we provide an initial report of the mechanical and
structural properties of human fetal left ventricle myo-
fibrils (the contractile organelles of striated muscle cells)
and isolated myosin, using isolated myofibril preparations
and purified actin and myosin (heavy meromyosin;
HMM) in an in vitro motility assay. In agreement
with reports by others (Sasse et al. 1993; Reiser et al.
2001), throughout the age range studied (52 to 134 days
of gestation), the fetal cardiac muscle predominantly
expresses the β-myosin heavy chain (β-MHC), and there
is a progressive increase in the relative proportion of
cardiac TnI (cTnI) to the total amount of TnI present
throughout gestation. We report that human fetal myo-
fibrils produce more force and have faster activation and
relaxation kinetics as they develop, and this is correlated
with maturation of sarcomere structure and myofibril
alignment. Unregulated F-actin filament sliding velocity
(Vf) on human fetal cardiac myosin decreased with age,
in agreement with a decrease in cross-bridge detachment
rate estimated from the early, slow phase of relaxation in
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Table 1. Fetal samples arranged by age, with experimental information
No. Sample age (days) Sample sex Self-reported ethnicity Myofibrils (no.) In vitro motility Electron microscopy imaging
1 52 n/a n/a 0 successful x
2 59 n/a n/a 5
3 74 female Caucasian 5
4 101 female Hispanic 12 x
5 105 female Caucasian 9
6 107 male Alaskan Native/ Caucasian 4
7 108 n/a n/a x
8 110 male African American 3
9 110 female Caucasian 9
10 114 male Native American 7
11 115 male Caucasian x
12 115 female African American 10
13 116 female n/a 23 x
14 127 male n/a x
15 130 male Asian 7
16 130 female Caucasian 1
17 134 male Asian (Korean) 4
myofibrils. The Vf of fetal cardiac myosin at 134 days is
close to the speed of human adult left ventricle myosin
(Moussavi-Harami et al. 2015). Our study is an important
step towards improved understanding of the development
of the human fetal heart contractile properties and we
conclude that the fetal left ventricle increases in force
production magnitude and speed as it ages from 52 to
134 days of gestation. A preliminary report of this work
were presented in abstract form (Racca et al. 2014).
Methods
Ethical approval and tissue preparation
Normal human fetal tissue was obtained by the Laboratory
of Developmental Biology at the University of Washington
with Internal Review Board approval from the University
of Washington and Seattle Children’s Research Institute,
using standards set by the latest revision of the Declaration
of Helsinki. Laboratory personnel from the Laboratory
of Developmental Biology collected specimens at clinics,
where a short time after passage in cold phosphate
solution, the specimens were examined, sexed and aged
(calculating the age in post-conception days). The age
range of fetuses for this project was 52–134 days of
gestation (see Table 1 for a list of samples). Samples were
stored in PBS at 4°C until dissection, for a period of 2–6 h.
The heart was identified and pieces of the outer wall of the
left ventricle were removed and placed immediately into
a skinning solution [relaxing solution with 50% glycerol
(by volume) and 1% Triton X-100, as previously described
(Brenner & Eisenberg, 1986; Regnier et al. 2000; Korte
et al. 2012)]. For the samples which were 52, 59 and
74 days of gestation, both the ventricles and the septum
may have been utilized. For a subset of samples, following
identification of the heart, sections of the left ventricle
were placed in 4% glutaraldehyde for electron micro-
scopy imaging. Because of the limited size of the samples,
samples used for electron microscopy were not able to
be used for contractile assays. Overall, 17 samples were
acquired and used in this project, collected over a period
of 14 months.
Adult heart tissue was obtained following written
informed consent from eight patients who were under-
going cardiac placement of a left ventricular-assist device
(7/8) or cardiac transplantation (1/8) for end stage heart
failure under a study protocol approved by the University
of Washington Institutional Review Board. Samples were
transported to the laboratory in cold PBS solution and
immediately prepared for use as detailed in below. Full
details of the patient study population were reported in a
previous publication (Moussavi-Harami et al. 2015).
Solutions for myofibril mechanics
Solutions for myofibril mechanics experiments were made
as previously described (Rao et al. 2014). Briefly, solution
composition was computed by an iterative algorithm that
calculates the equilibrium concentration of ligands and
ions based on published affinity constants (Fabiato, 1988).
Relaxing and activating solutions contained (in mM): 80
Mops, 15 EGTA, 1 Mg2+, 5 MgATP, 83 K+, 52 Na+ and 15
creatine phosphate, pH 7.0 at 15°C; solution ionic strength
was 170 mM. For adult myofibrils, the concentration of
MgATP was 2 mM. The Ca2+ concentration (expressed as
pCa = –log [Ca2+]) was set by adjusting the amount of
CaCl2.
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Myofibril mechanics
Muscle samples were demembranated for 24 h at
4°C in relaxing solution containing 50% glycerol (by
volume) and 1% Triton X-100, as previously described
(Brenner & Eisenberg, 1986; Regnier et al. 2000). The
demembranated muscle tissue was then transferred to a
50% glycerol-relaxing solution and stored at –20°C for use
up to 1 week.
To obtain isolated small bundles of myofibrils (average
width of bundles 6.5 ± 0.2 μm), small pieces of muscle
tissue were placed into rigor solution (in mM): 50 Tris,
100 KCl, 2 MgCl2, 1 EGTA, 2 dithiothreitol (DTT), pH 7,
containing a 1:200 dilution of protease inhibitor cocktail
(Sigma-Aldritch, St. Louis, MO, USA). After two rinses in
rigor solution, the tissue was shredded with a high speed
homogenizer for one or two bursts of 15 s. Myofibrils were
stored at 4°C and used within 3 days.
Myofibril experiments were performed as previously
described (Colomo et al. 1997; Racca et al., 2013, 2015;
Moussavi-Harami et al. 2015).
Specific passive force was measured for a subset of pre-
parations after stretching the myofibril bundle 10% above
its resting length, which resulted in a sarcomere length of
2.3 μm. Activation and relaxation data were collected at
15°C and fit with linear regression as previously described
(Kreutziger et al. 2008; Racca et al., 2013, 2015). A t1/2
estimation was used in place of a single-exponential fit
because the rate of rise or fall in force was not well
described by a single exponential, and this was converted to
a rate using the equation: 1/t1/2 (Racca et al. 2013). Briefly,
the activation rate (kACT; with rapid increase in Ca2+) was
estimated from the time to reach 50% maximal activation.
Forces measured were standardized to cross-sectional area
of the myofibril and reported as specific force (FMAX,
mN mm−2). Relaxation rate for slow phase (kREL,slow) was
reported as the slope of a regression line fit to the tension
trace and normalized to the tension amplitude, and the
duration of the slow phase was measured from the onset
of solution change at the myofibril to the shoulder marking
the beginning of the fast phase. The transition from the
slow to rapid phase was determined through multiple
factors, including an apparent change in the slope of the
data or a change in the signal-to-noise ratio which was
often apparent at the transition (Fig. 1B). The relaxation
rate for the fast phase (kREL,fast) was estimated from the
time to 50% reduction in force.
In vitro motility assay
Myosin and F-actin preparation. Cardiac myosin was pre-
pared according to previously described methods and
stored at 4°C in a storage solution (in mM: 600 KCl,
10 Tris, 2 MgCl2, 5 DTT, pH 7.6) for up to 3 days
(Margossian & Lowey, 1982). Aliquots of the myosin
were digested to HMM by enzymatic digestion with tosyl
lysine chloromethyl ketone (TLCK)–chymotrypsin (50 mg
ml−1; Sigma) (Kron et al. 1991a, b). HMM was pre-
pared daily. The concentration of HMM and myosin
was determined using spectrophotometry as previously
described (Clemmens & Regnier, 2004). Rabbit skeletal
F-actin was prepared from muscle ether powder, labelled
with rhodamine–phalloidin (Molecular Probes, Eugene,
OR, USA) as previously described (Pardee & Spudich,
1982; Spudich et al. 1982; Kron et al. 1991a, b), stored at
4°C and used within 6 weeks.
Flow cells were prepared as previously described
(Gordon et al. 1997; Clemmens et al. 2005). Briefly, two
glass coverslips, one 22 mm x 60 mm (VWR Scientific,
West Chester, PA, USA) and one 18 mm2 (Corning, Horse-
heads, NY, USA), were separated by 2 mm adhesive foam
spacers. The larger coverslip surface was first cleaned and
coated with 1% nitrocellulose in amyl acetate (Sigma) and
allowed to dry.
F-actin filament velocity (Vf) experiments. Unregulated
F-actin filament motility was measured at 30°C.
Experimental procedures were as previously described
(Razumova et al. 2006). At least six unique areas of each
assay chamber were recorded for 10 s each at 10 Hz.
Recordings were analysed digitally, using custom software
developed in house. The criteria for inclusion/exclusion
of filaments and additional information on this method
are detailed in the statistics section below, and in previous
publications (Homsher et al. 1992; Racca et al. 2013).
Contractile protein isoform composition. To determine
MHC isoform composition, samples were dissected from
the left ventricles utilized in the functional studies and
prepared for SDS-PAGE. Briefly, left ventricle tissue was
homogenized in CellLytic (Sigma), with the addition
of protease inhibitors, using a glass mortar and pestle
chilled on ice. Protein concentrations were determined
using a Bradford assay (Bio-Rad Laboratories, Hercules,
CA, USA). The myosin isoforms in these samples were
separated as previously described (Van Hees et al.
2007) using a Mini-PROTEAN Tetra Cell (Bio-Rad
Laboratories). The stacking gel was 4% acrylamide (pH
6.8) and the separating gel contained 7% acrylamide
(pH 8.8) with 30% (v/v) glycerol. Gels were run for
16 h at 4°C. Gels were then stained with SYPRO
Ruby (Molecular Probes) following the manufacturer’s
instructions and imaged using a BioSpectrum Imaging
System (UVP, Upland, CA, USA).
To determine the contractile protein isoform compo-
sition in human fetal left ventricle muscle SDS-
PAGE and Western blotting was used. In brief,
human fetal and adult left ventricle samples were
separated on 10% or 12% SDS-PAGE gels using a
Mini-PROTEAN Tetra Cell (Bio-Rad Laboratories). The
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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SDS-PAGE gel was transferred onto a polyvinylidene
fluoride (PVDF) membrane using the Mini-PROTEAN
Tetra Cell wet transfer system (Bio-Rad Laboratories).
The primary antibodies used were as follows: cTnI
(sc-15368, Santa Cruz Biotechnology, Santa Cruz, CA,
USA), ssTnI (sc8119, Santa Cruz), cTnT (sc8121,
Santa Cruz), GAPDH (Rockland Immunochemicals,
Gilbertsville, PA, USA); and the α-MHC (BAG5) and
β-MHC were a gift from Charles Murry (University of
Washington). There were two to five technical replicates
for each sample, and two biological replicates (two separate
fetal hearts aged 130 days). Images were analysed using
ImageJ software (National Institutes of Health, Bethesda,
MD, USA). Troponin expression was first standardized to
GAPDH and the expression levels were normalized to the
134-day-old sample.
































































































































































































Figure 1. Human fetal left ventricle myofibril kinetics from 55 to 134 days of gestation
A and B, representative myofibril force traces for human fetal left ventricle myofibrils at 74 days of gestation
(light grey) and 134 days of gestation (dark grey) and human adult stage IV heart failure left ventricle myofibrils
(black). A, activation traces showing activation kinetic differences between human fetal left ventricle myofibrils
at 74 and 134 days of gestation and adult left ventricle myofibrils; y-axis is force normalized to each myofibril’s
specific force at maximal calcium concentration (FMAX); bar shows 5s. Inset, activation trace showing magnitude
of activation; vertical bar shows 10 mN mm−2; horizontal bar shows 5 s. B, relaxation traces showing relaxation
kinetic differences between human fetal left ventricle myofibrils at 74 and 134 days of gestation and adult left
ventricle myofibrils; y-axis is force normalized to each myofibril’s specific force at maximal calcium concentration
(FMAX); bar shows 5 s. Inset, close-up of the slow phase of relaxation of the myofibrils (bold lines), in response to
a change from maximum [Ca2+] (pCa 4.0) to minimum [Ca2+] (pCa 9.0), showing slow phase kinetics; vertical
bar shows 10% Fmax; horizontal bar shows 100 ms. Straight lines indicate the slow phase fit (kREL,slow); bold lines
indicate data considered part of the slow phase; thin lines indicate the total normalized relaxation data. C–H,
changes in the kinetics and force of fetal left ventricle myofibrils grouped by the age of gestation, compared
to human adult. C, specific passive force in relaxing solution (FPASS); D, specific force production at maximum
concentration of calcium (FMAX); E, the rate of activation (kACT); F, the duration of the slow phase of relaxation
(tREL,slow); G, the rate of the slow phase of relaxation (kREL,slow); H, the rate of the fast phase of relaxation (kREL,fast).
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Electron microscopy imaging. For ultrastructural deter-
mination, same-day dissected tissues from human fetal
heart muscle of three different fetuses (at 52, 108 and
127 days of gestation) were fixed in 4% glutaraldehyde
and stored at 4°C until processing. The tissues were then
post-fixed in osmium tetroxide, dehydrated with ethanol
and embedded in Poly/Bed 812 epoxy resin. Ultrathin
longitudinal sections were stained with lead citrate and
viewed and photographed on a JEOL 1230 transmission
electron microscope (Jeol USA Inc., Peabody, MA, USA).
Images were analysed using ImageJ software (National
Institutes of Health).
Statistics
Myofibril experiments. All values in Tables 2 and 3 are
reported as means ± SEM. The number of fibrils (n)
in each mean is also reported, as well as the number of
fetuses or adult samples (N). A one-way ANOVA with a
Tukey post-hoc test was used to compare between myofibril
groups with statistical significance set at P < 0.05.
In vitro motility. Mean speed and error of mean speed
were weighted according to the duration of the filament
trace and the number of filaments per slide (Racca et al.
2013) and are described briefly below.
Using a previously described filtering technique (the
Homsher–Sellers ratio), in which a ratio of mean to SD of
velocity was used to eliminate erratically moving filaments,
the optimal ratio for this study (0.6) was determined by
analysing recordings with a motility solution [ATP] =
2 mM. Filaments that moved erratically were not included
in the analysis. Erratic filaments stalled, crossed paths with
another filament, crossed themselves or pulled apart into
separate pieces.
Additional statistical analysis was performed on in vitro
motility data to propagate uncertainties associated with
filament speeds. This statistical analysis was based on prior
reporting (Homsher et al. 1992; Clemmens & Regnier,
2004; Racca et al. 2013). Filament mean speeds (u) and
standard deviations (σ) were weighted according to the
number of frames a filament was present and the number
















Overall 17 human fetus samples were acquired for this
project, with the greatest number (N = 10) being between
101 and 116 days of gestation. Samples outside this age
range were rare due to regulatory limits (illegal at >
24 weeks, 168 days of gestation) and alternative procedures
available (Mifeprex for < 9 weeks, 63 days of gestation).
Table 1 describes the age, sex, reported ethnicity and
which experiments each sample was used for. Two
samples were acquired at 130 days of gestation for myo-
fibril experiments, one at 127 days of gestation for
electron microscopy analysis only, and one at 134 days
of gestation for use in myofibril and in vitro motility
assays. One fetal heart sample was collected from a 52
day fetus, but it did not produce functional myofibrils,
so it was used only for electron microscopy imaging.
The other two younger age fetal samples were at 59
and 74 days of gestation, and both were used for myo-
fibril experiments only. These samples are typically small
and fragile, especially with respect to those < 100 days
of gestation. As such, very few functional myofibrils were
obtained from the younger ages. Samples that were within
3 days of each other were pooled for myofibril analysis in
an effort to improve statistical power, although generating
statistically significant differences in these samples was
still a challenge. Therefore, the results presented below
should not be considered definitive until additional studies
can confirm them. Additionally, because we were limited
in the tissue we could obtain, we chose to prioritize
measurements of the contractile properties for the current
study, and used additional available tissue for limited
protein and structural analysis.
For comparison with human fetal samples, human
adult samples were collected from eight patients who were
enrolled in the study. Six out of eight patients (75%) were
males and the average age of the cohort was 48 ± 15
years (24–67 years). The etiology of heart failure in all
patients used in the study was non-ischaemic. Details
for this patient population have been reported previously
(Moussavi-Harami et al. 2015).
Myofibril passive force and sarcomere length
Myofibrils were stretched to 110% slack length. If
sarcomeres were visible, which was the case for a majority
of the myofibrils, the sarcomere length at this stretch was
recorded, and on average, was shown to be 2.3 μm per
sarcomere. Before activation, passive force was measured.
The average specific passive force (FPASS) varied greatly
between the fetal ages (Table 2). FPASS was highest at
101 days (12.5 ± 1.8 mN mm−2; n = 11), and lowest
at 114–116 days mN mm−2 (4.0 ± 0.7 mN mm−2; n = 38)
(P < 0.05 between these two groups) (Fig. 1C). This
variation did not appear to be a function of the average
width of the preparations (4.7–7.2 μm, Table 2). Overall,
FPASS was much lower than what is seen for adult stage IV
heart failure ventricle samples (27 ± 7 mN mm−2; n = 8;
Table 2) (P < 0.01 vs. all fetal groups).
C© 2015 The Authors. The Journal of Physiology C© 2015 The Physiological Society
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Table 3. FMAX and kinetic parameters for submaximal [Ca2+] activation (pCa 5.8) and relaxation of fetal myofibrils at 15°C
Parameter Specific FpCa5.8
(units) (mN mm−2) % of FMAX kACT (s−1) tREL,slow (s) kREL,slow (s−1) kREL,fast (s−1)
74 days (N = 1) 17.5 ± 5.6 (5) 87 ± 29 (5) 0.34 ± 0.07 (4) 0.211 ± 0.034 (4) 0.30 ± 0.08 (4) 1.15 ± 0.17 (5)
115 days (N = 1) 27.2 ± 5.6 (18) 74 ± 5 (16) 0.61 ± 0.08 (18) 0.142 ± 0.011 (18) 0.35 ± 0.04 (18) 2.11 ± 0.18 (18)
134 days (N = 1) 26.4 ± 3.5 (3) 62 ± 12 (3) 0.40 ± 0.11 (3) 0.142 ± 0.041 (3) 0.40 ± 0.24 (2) 2.26 ± 0.71 (2)
Data are mean ± SEM, N indicates the number of separate fetal samples at a particular age and numbers in parentheses represent
the number of myofibrils. The % of FMAX is calculated as FpCa5.8/FpCa4.0 for each myofibril.
Myofibril activation and relaxation kinetics
Myofibrils were exposed to rapid solution switching for
step increases and decreases in Ca2+, from pCa 9.0 to 4.0
and back to 9.0 (see Methods), to determine the magnitude
and rate of force generation and relaxation at 15°C.
Representative myofibril force traces from 74 and 130 days
of gestation fetal tissue samples and one from adult stage
IV heart failure sample are shown in Fig. 1 for activation
and relaxation. These traces demonstrate that the 74 day
myofibrils produce much less force (Fig. 1A, inset) and
have a slower rate of force development (Fig. 1A) and
relaxation (Fig. 1B) than 134 day fetal and adult stage IV
heart failure myofibrils. The data for all the fetal and adult
myofibrils are summarized in Fig. 1(C–H) and quantitative
values are reported in Table 2. The average width of the
preparations varied by as much as 35%. We normalized
the active maximal force per myofibril bundle to the width
of the bundle, yielding maximal specific force, and fetal
myofibrils produced progressively more maximal specific
force (FMAX) as they aged. FMAX at 59 days (7.8 ± 3.0
mN mm−2; n = 3) was one-third of the force produced
at 74 days (23.1 ± 8.3 mN mm−2; n = 5) and 101 days
of gestation (25.2 ± 6.6 mN mm−2; n = 11). At 105–107
days of gestation (36.9 ± 10.6 mN mm−2; n = 13) and
114–116 days of gestation (26.9 ± 4.8 mN mm−2; n = 39)
FMAX was three- to four-fold higher compared with the
59 days of gestation value. At 130 days of gestation FMAX
(49.9 ± 9.3 mN mm−2; n = 8) increased further, being
six-fold greater than the 59 day values. However, even at
130 and 134 days of gestation, FMAX was still considerably
less than that of adult left ventricle samples from either
stage IV heart failure patients (75.2 ± 10.6 mN mm−2) or
presumed healthy controls as reported by others (90–110
mN mm−2; Piroddi et al. 2007; Belus et al. 2008).
The rate of force production (kACT; Fig. 1A, E and
Table 2) represents the processes of Ca2+-dependent
thin filament activation, myosin cross-bridge binding
and force production. kACT for fetal myofibrils increased
progressively as myofibrils aged (Table 2). Compared with
59 days (0.27 ± 0.07 s−1; n = 4), kACT increased 60% by
74–107 days of gestation, and had tripled by 114–116 days
(1.04 ± 0.08 s−1; n = 38), P < 0.05 vs. 59 days) of gestation.
For the two samples of 130 days of gestation, kACT was still
considerably higher (0.98 ± 0.21 s−1; n = 8) compared
with the sample of 59 days of gestation, although with the
low number of myofibrils from limited samples, this was
not statistically significant. The 134 day sample was much
slower to activate than both of the 130 day samples, but
this may an artifact of sample collection and/or handling
given that the single sample provided only four functional
myofibrils, and these myofibrils also produced less force
(36.0 ± 12.1 mN mm−2; n = 4) than the myofibrils at
130 days of gestation. At days 114–116, myofibrils from
fetal ventricle samples produced force at a faster rate than
those from adult stage IV heart failure ventricle samples
(0.61 ± 0.07 s−1; n = 16; P < 0.05 vs. 114–116 days) and
what has been reported by others from presumed healthy
control adult ventricle tissue (0.73–0.84 s−1; Piroddi et al.
2007; Belus et al. 2008). They also produced force at
a slower rate than that reported for presumed healthy
control adult atrial tissue (3.7 s−1; Piroddi et al. 2007;
Belus et al. 2008).
Fetal cardiac myofibril relaxation also increased in speed
with age, as described by the time to 50% (tREL,50). At
59 days (0.59 ± 0.06 s; n = 2) and 74 days (0.73 ± 0.05 s;
n = 5), myofibrils were relaxing more than 50% slower
than at 101 days (0.40 ± 0.03 s; n = 12; P < 0.05 vs.
74 days) and older. This was even more pronounced by the
time to 90% relaxation (tREL,90), which gradually decreased
as myofibrils aged from 59 days (15.5 ± 2.0 s; n = 3) to
nearly half that time at 101 days (7.3 ± 2.1 s; n = 9), and
one-third of the time by 114–116 days (5.1 ± 0.8 s; n = 37;
P < 0.05 vs. 59 days). The time to 90% relaxation was
prolonged in all the fetal samples compared with the adult
stage IV heart failure samples (3.5 ± 0.6 s; n = 15). This
difference in relaxation speed is shown in Fig. 1B, which
compares example myofibril traces in adult sage IV heart
failure and at 74 and 130 days of gestation and summarized
in Table 2.
Force relaxation in myofibrils is characterized by an
initial slow (kREL,slow, tREL,slow; Fig. 1B, inset) and secondary
fast (kREL,fast; Fig. 1B) phase. kREL,fast is thought to reflect
the phenomenon of sarcomere give, in which uneven
sarcomere lengths during relaxation create more strain on
nearby sarcomeres, causing a propagation of sarcomere
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release (Poggesi et al. 2005), and may be independent of
the Ca2+ sensitivity of the myofilament (De Tombe et al.
2007). Compared with 59 days (1.18 ± 0.13 s−1; n = 2) and
74 days (0.96 ± 0.05 s−1; n = 5), kREL,fast was 50% faster
for 101–134 day samples (Fig. 1F; Table 2). However, even
at 130 days myofibrils from the fetal heart ventricle samples
relaxed at rates about 20% greater (1.86 ± 0.24 s−1;
n = 7) than those from adult stage IV heart failure left
ventricle (1.55 ± 0.14 s−1; n = 21) and at much slower
rate compared with the reported values by others for pre-
sumed healthy control adult ventricle (2.9 s−1) and atrial
(16.0 s−1) tissue (Piroddi et al. 2007; Belus et al. 2008).
The early, slow phase rate of relaxation, kREL,slow, is
thought to be determined by the rate of cross-bridge
detachment during maximal Ca2+ activation (Tesi et al.
2002). In contrast to kREL,fast, kREL,slow (Fig. 1G) increased
progressively from 59 days (0.14 ± 0.03 s−1; n = 3)
to 74 days (0.22 ± 0.05 s−1; n = 5) and 101 days
(0.32 ± 0.08 s−1; n = 11). It appeared to decrease again
with the 130 day samples (0.11 ± 0.02 s−1; n = 8).
At 101 and 110 days, the kREL,slow values are closer to
those seen in adult stage IV heart failure ventricle samples
(0.30 ± 0.04 s−1; n = 19). Interestingly, kREL,slow for pre-
sumed healthy control human adult ventricle was reported
to be 0.15–0.17 s−1, half of what we report at 101 days and
in our stage IV heart failure adult samples, but close to
what we report at 59 and 130–134 days, while the human
adult atria kREL,slow is reported to be faster (0.52 s−1;
Piroddi et al. 2007; Belus et al. 2008).
We have previously reported that the slow phase
duration (tREL,slow) may be influenced by the properties
of thin filament regulatory proteins and the level of Ca2+
activation (Kreutziger et al. 2008, 2011). There was a 35%
decrease in tREL,slow, from 59 days (0.292±0.035 s; n=4) to
101 days (0.192 ± 0.013 s; n = 11) and it remained around
200 ms at later time points out to 134 days. However,
outside of the initial time point at 59 days vs. 114–116
days (0.180 ± 0.007 s; n = 39), the other prenatal time
points for tREL,slow do not differ significantly from one
another. The duration of the slow phase for older fetal
tissues was close to what we found in adult stage IV heart
failure left ventricle tissues (0.203 ± 0.012 s; n = 21).
These older fetal ventricle values are slower than what has
been reported for control human adult ventricles at pCa
4.0 by others (0.225–0.226 s), and faster than what is seen
in human adult atria myofibrils (0.126 s) (Piroddi et al.
2007; Belus et al. 2008).
We also activated a subset of myofibrils of different
gestational ages at a submaximal concentration of calcium
(pCa 5.8; Table 3) to examine possible changes in calcium
sensitivity. To avoid bias due to run-down of the myo-
fibrils, half of the myofibrils were first activated at pCa
5.8, then following relaxation, activated at pCa 4.0.
This order was reversed for the other half of the myo-
fibrils. The force production at this submaximal calcium
appeared to decrease with age, suggesting a decrease in
calcium sensitivity as the fetal heart ages from 74 to
134 days of gestation. At 74 days, the force produced at
pCa 5.8 was 87% of the force produced at maximum
calcium concentration (pCa 4.0). At 114–116 days, pCa 5.8
produced only 74% of maximum force, and by 134 days
of gestation this was reduced to only 62% of the force
produced at pCa 4.0, indicating fetal heart ventricle myo-
fibrils have elevated calcium sensitivity compared with
adult ventricle myofibrils. In addition to a higher calcium
sensitivity, fetal ventricle myofibril activation rates at
pCa 5.8 were 95% (74 days), 74% (115 days) and 71%
(134 days) of the activation rates of the same myo-
fibrils at pCa 4.0. These results suggest there may be
a gradual decrease in the calcium sensitivity of myo-
fibril contraction. Finally, the duration of the slow phase
of relaxation following activation at pCa 5.8 was 94%
(74 days), 83% (115 days) and 79% (134 days) the duration
of the same myofibril following activation at pCa 4.0
(Table 3). This decrease in the slow phase of relaxation
may indicate a change in Ca2+ release rate of troponin is
altered throughout gestation.
Fetal cardiac myosin sliding velocities
The slow activation and relaxation kinetics of fetal myo-
fibrils (compared with adult myofibrils) suggested much
slower fetal myosin cross-bridge cycling and ATPase
activity. To investigate this we measured sliding velocity
of F-actin (Vf) propelled by HMM prepared from fetal
human left ventricle tissue of three fetuses (101, 116 and
134 days of gestation) in the in vitro motility assay, where











































Figure 2. Unregulated F-actin filament sliding velocity of fetal
human left ventricle decreases with age
The speed of smoothly moving actin filaments (VMAX) over fetal
human left ventricle heavy meromyosin from 101, 116 and 134 days
of gestation. Data shown are as weighted mean and weighted SD.
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of regulatory proteins and at a temperature that is closer
to physiological than can be used in myofibril mechanical
assays. Maximal sliding velocity (VMAX, measured at 30°C)
for fetal HMM at 101 days was 4.03 ± 0.62 μm s−1, almost
two-fold faster than VMAX at 134 days (1.98 ± 0.76 μm
s−1). This was consistent with faster kREL,slow at 100 vs.
134 days, and suggests myosin cycling and cross-bridge
detachment may decrease over this time period (Fig. 2).
Contractile protein expression
Human fetal left ventricle contained both ssTnI and
cTnI protein isoforms as confirmed by Western blot
(Fig. 3A). We observed a progressive increase in the relative
proportion of cTnI to the total amount of TnI present as
the fetal heart aged, in agreement with others (Sasse et al.
1993), and its increase in density was similar to what was
seen for the total amount of troponin T (Fig. 3B, C).
Using both the C-19 and the mAB13-11 cardiac TnT anti-
bodies, we detected a total of three bands in fetal cardiac
tissue and two in the adult failing left ventricle, consistent
with Anderson et al. (1991) (Fig. 3B). However, in the
current study there was a clear predominant TnT isoform
(TnT3) in the fetal left ventricle and the other two iso-
forms detected were of low abundance. Troponin density
(Fig. 3, normalized to GAPDH) indicated an increase in
protein density within the tissue as a function of fetal age.
We found β-MHC expressed in human fetal left ventricle
and adult ventricle samples (Fig. 4) at all ages, with little to
no expression of α-MHC, which is consistent with reports
by others (Reiser et al. 2001) of only 0–3% α-MHC at
110 days of gestation. To confirm that no α-MHC was
present, we used a tissue sample of rat atria and ventricle,
which demonstrates that α-MHC is present in the rat atria
and ventricle, but not visible in the human fetal or adult
ventricle samples.
Electron microscopy and ultrastructure of fetal left
ventricle muscle
To elucidate the potential influence of structure on the
functional changes in these fetal tissues, sections of left
ventricle from 52, 108 and 127 days of gestation were
imaged using electron microscopy (Fig. 5). The small
size of the samples meant that it was not possible to use
the same sample for imaging and mechanical analysis.
Because pre-treatment was not possible, these samples
were fixed in varying states of contraction; most notably,
the 108 day sample appears to be fully contracted, while
the 52 day sample appears to be relaxed. We therefore
focused on features, such as the widths of the myofibrils
and structure of the contractile apparatus, that would
build on previous observations (Kim et al. 1992). Within
the myofibrils at day 52, z-bands were crooked and did
not align between adjacent myofibrils, myofibrils were
very narrow in width at the Z-band (0.36 ± 0.02 μm;
n = 90) and the muscle had low myofibril density
(Fig. 5A). Correlating with a doubling in force production













































































































































Figure 3. Troponin I and troponin T expression in human fetal
left ventricles
A, Representative Western blot of cardiac troponin I (cTnI), slow
skeletal troponin I (ssTnI) and a loading control GAPDH from human
fetal left ventricles between the ages of 74 and 134 days of
gestation and adult failing left ventricle (Adult). B, representative
Western blot of cardiac TnT expression in human fetal left ventricles
using both a C-19 and mAb13-11 antibodies (top and bottom panel,
respectively); Adult – adult failing left ventricle, Rat LV – adult rat left
ventricle, Rat A – adult rat atrium. C, normalized expression of
troponin across the age range of fetal ventricle samples. Top panel
shows normalized expression of cTnI and ssTnI, bottom panel
normalized expression of TnT (calculated from the predominant
isoform, labelled 2, from the C-19 Western blots). Data are
mean ± SEM; there were two to five technical replicates for each
sample, and two biological replicates (two separate fetal hearts aged
130 days). Troponin expression was first standardized to GAPDH and
the expression levels were normalized to the 134 day sample.
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across adjacent myofibrils, and myofibrils were noticeably
wider (0.457 ± 0.01 μm; n = 297) (Fig. 5B). Finally, at
day 127, the muscle had greater myofibril density and
myofibril width approximately doubled from day 108
(0.97 ± 0.02 μm; n = 427) (Fig. 5C). At all three ages
we observed the thick filament (H zone) region was often
not distinct, consistent with previous observations (Kim
et al. 1992). However, our ability to study this in detail
was limited, due to the small amount of tissue available
for these measurements and to some inconsistency in
the time between tissue harvesting and fixation that was
unavoidable.
Discussion
Here we report for the first time changes in the contra-
ctile properties of human fetal cardiac muscle during
59–134 days of gestation and compare them with human
adult stage IV heart failure muscle. We characterized
several kinetic parameters of contraction and relaxation
that are altered during the maturation of the fetal heart
which correlate with changes in sarcomeric protein iso-
forms and maturation of sarcomere structure and myo-
fibril organization within cardiomyocytes.
Force production
The force produced by human fetal left ventricle myofibrils
increases considerably as the fetal heart ages (Fig. 1 and
































































Figure 4. Myosin heavy chain expression in human fetal left
ventricles
A, SYPRO ruby stain for total protein (top panel) and Western blot
(bottom panel) showing β myosin heavy chain (MHC) expression in
fetal left ventricle samples across the range 74–134 days of
gestation. MHC was separated using 7% acrylamide and 30%
glycerol gels (Van Hees et al. 2007). B, Western blot for α-MHC (top
panel) and β-MHC (bottom panel) in a subset of fetal left ventricle
samples. Rat left ventricle and atrium were used as a control for
α-MHC and proteins were separated using a 10% acrylamide gel.
Adult – failing adult left ventricle, Rat LV – adult rat left ventricle.
fetal left ventricle myofibrils still produced considerably
less specific force than our stage IV heart failure human
adult ventricle myofibrils and less than half the specific
force previously reported for presumed healthy adult
ventricle myofibrils (Piroddi et al. 2007). There are at
least two potential explanations for the gain in force
production from 59 to 134 days of gestation. (1) The
ultrastructure of the fetal cardiac myofibrils undergoes
significant development and remodeling; in particular the
width and alignment of z-discs increases and the overall
width of myofibrils increases. This allows more force to
be translated along the sarcomeres and the myofibril. In
the small bundles used for mechanical measurements, the
older bundles contain more sarcomeres that are aligned
and allow force to be translated laterally. (2) Myosin
density within the sarcomere increases, increasing the
number of cross-bridge bindings and thus force generating
capacity.
We have previously reported that human fetal skeletal
muscle ultrastructure is underdeveloped at 108 days of
gestation (Racca et al. 2013). In addition, Kim et al.
(1992) demonstrated that later term human fetal hearts,
at 119 days of gestation, had myofibrils that were short,
loosely packed and lacking consistently definitive Z-bands.
In the current study, we found that cardiac muscle
ultrastructure also lacks order at 52, 108 and 127 days
of gestation, although there are considerable increases in
the width and alignment of myofibril z-discs between these
time points. These results are consistent with studies on
the ultrastructure of fetal lamb and guinea pig, which
showed that as the fetal heart ages myofibril density of
cells increases, elongation and alignment of neighbouring
myofibrils increase, and myofibrils widen in diameter
(Sheldon et al. 1976; Rolph et al. 1982). We are unable to
address changes in sarcomere length due to our inability
to pre-treat samples prior to placement in the electron
microscopy buffer. The lack of order in the structure of
the myofibril can at least partially explain the low force
production compared with adult myofibrils, as trans-
mission of strain generated by myosins may be less
efficient. This effect could be compounded by differences
in the series elastic components of sarcomeres. Moreover,
as the myofibril ultrastructure develops between 59
and 134 days of gestation the longer and wider myo-
fibrils would have increased acto-myosin interaction.
This change in ultrastructure probably contributes to
the increase in force and some of the increases in the
kinetics of activation and relaxation throughout gestation.
Finally, the possibility that the myofibril bundles contain
non-aligned or non-sarcomeric tissue cannot be excluded,
as the electron microscopy images indicate that sections
of laterally joined myofibrils are thin, especially in the
younger aged myofibrils, and while the preparations were
chemically skinned with both glycerol and Triton, some
non-sarcomeric tissue may remain.
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Studies in fetal mice report that the overall increase in
myosin density is a key player in an age-correlated increase
in force production (Siedner et al. 2003). In the current
study, we were unable to show a change in myosin density
within the age range examined, but we report a small
increase in overall TnI and TnT density. As the overall
density of the contractile proteins can change as a result
of either an increase in the number of myofibrils or an
increase in the size of the myofibrils within a cell, both of
which are shown to occur with the electron microscopy
work (Fig. 5). Together, the increase in troponin density
per cell (Fig. 3) and the increase in myofibrils seen by
electron microscopy (Fig. 5) suggest an overall increase in
myofibril protein density per cell and lend more support
to the idea that ultrastructural maturation plays a key role
in increasing force production in the developing human
fetal heart.
Kinetics of activation and relaxation
We have reported here that the activation and relaxation
kinetics of myofibrils from human fetal left ventricle
increase in speed as the fetal heart ages. At 130–134 days
of gestation relaxation is faster than our adult stage IV
heart failure ventricle samples, but significantly slower
than what has been reported for a control population
of adult ventricle myofibrils (Piroddi et al. 2007). This
is the case even though the predominant myosin isoform
expressed is β-MHC at all time points (Fig. 4B).
One likely mechanism for the increase in activation and
relaxation kinetics is that the ultrastructure development
between 59 and 100 days of gestation allows for better
Z-disc and sarcomere alignment within the small bundles
of myofibrils used in our experiments, which may decrease
compliance and cause strain to translate across the myo-
fibril more efficiently (Martyn et al. 2002). This may
affect the kinetics of force development even more than
the magnitude. Additionally the thick and thin filaments
are more tightly bundled, which could increase the inter-
action efficiency of myosin and actin (Williams et al. 2010,
2013). This increase in ultrastructural order could also be
responsible for variation in cross-bridge detachment rates
seen in the myofibril slow phase (Figs 1G and 5); the over-
all myosin density may increase during this period and
reach a critical density where the myosin and actin can
better interact. However, we could not study this with
the limited number and quality of samples available for
structure and protein analysis. Also, changes in myosin or
troponin proteins (from ssTnI to cTnI) cannot be ruled
out as having influence on the changing kinetics of the
human fetal heart as it develops.
The data from the myofibril kREL,slow measurements
and the maximum velocity of unregulated actin filament




Figure 5. Ultrastructural assessment of human fetal left ventricle
Transmission electron micrographs of left ventricle sections from three fetal hearts at 52, 108 and 127 days of
gestation. All scale bars are 2 μm. A, top, 52 day left ventricle appears to be relaxed, with longer sarcomere
length, and shows thick filament presence and thin myofibrils (average width 0.36 ± 0.02 μm; n = 90). A,
bottom, 52 day left ventricle shows poor z-disc alignment between myofibrils, wavy z-discs within myofibrils
(arrow) and low myofibril density. B, top, 108 day left ventricle appears to be in a contacted state with very short
sarcomere lengths, and shows definitive m-line within sarcomeres. B, bottom, 108 day left ventricle shows medium
myofibril density and z-disc alignment between adjacent myofibril (arrow). Average width of segment of myofibrils
is 0.457 ± 0.01 μm (n = 297). C, top, 127 day left ventricle appears to be relaxed with long sarcomere lengths,
and shows definitive m-line within sarcomeres. C, bottom, 127 day left ventricle shows high myofibril density
and z-disc alignment between adjacent myofibril (arrow), as well as larger myofibril widths overall (average width
0.97 ± 0.02 μm; n = 427).
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cross-bridge detachment rate slows considerably between
100 and 130 days of gestation. This is the opposite
of what we might have expected due to the increase
in contractile kinetics in myofibrils. VMAX with myosin
from the 101 and 116 day fetal left ventricle was much
slower than we have shown for adult fast skeletal myo-
sin (gene MYH2; Racca et al. 2013) and myosin from
rat hearts (Regnier et al. 2000), but faster than speeds
reported from adult human myosin (Moussavi-Harami
et al. 2015). The VMAX of the myosin from the 134 day
sample was similar to that reported for myosin from
adult human (Moussavi-Harami et al. 2015). We found
that kREL,slow of adult stage IV heart failure myofibrils
is comparable to that of fetal samples at 101 days, and
faster than that of fetal samples at 130–134 days. One
potential explanation for these changes in cross-bridge
cycling kinetics is a change in the MHC isoform expressed.
However, in the current study, we were only able to detect
β-MHC in the fetal and adult ventricle samples using
both Western blots and SYPRO staining. In contrast, pre-
vious work has shown that the human fetal left ventricle
contains a small amount of α-MHC (<5%) and that there
is a significant reduction in α-MHC from 47 to 100 days
of gestation (Reiser et al. 2001). However, in a study by
Krenz et al. (2003) a 40% change in MHC (from α-MHC
to β-MHC) only resulted in a 20% reduction in VMAX.
Moreover, previous work has demonstrated that the VMAX
in unregulated in vitro motility assays is not affected by
small changes in MHC isoform composition (Cuda et al.
1997). Therefore, even if there was a small amount of
undetected α-MHC present, which varied between the
gestational ages, it is unlikely to be responsible for the
50% reduction in VMAX that was observed between
the 101 and 134 day samples. Another possible explanation
for the changes in cross-bridge kinetics is either an
altered isoform or phosphorylation state of the myo-
sin light chains (Karabina et al. 2015). The mechanism
responsible for the observed change in cross-bridge
kinetics throughout human fetal heart development
deserves future investigation.
Changes to the calcium sensitivity of the myofilament
affect the activation kinetics and the duration of the
initial, slow phase of relaxation (Poggesi et al. 2005;
Kreutziger et al. 2011). A decrease in calcium sensitivity
caused by a change in the properties of TnC could cause a
decrease in the rate of activation (Kreutziger et al. 2011).
However, the resulting decrease in calcium sensitivity we
see in the human fetal heart is instead accompanied by
a slight increase in the rate of activation. The duration
of the slow phase is an indication of the thin filament
‘on’ period and this shortens between 59 and 100 days
of gestation. A shorter thin filament ‘on’ period may
be consistent with lower calcium sensitivity (Kreutziger
et al. 2011). We hypothesize that this shorter filament ‘on’
period is the result of either (1) decreased thin filament
compliance, caused by more tightly bound thick and thin
filaments, resulting in better translation of one troponin
subunit turning ‘off’ affecting its neighbour; (2) a change
in TnI isoform, switching to the adult cTnI isoform from
the fetal cardiac/ssTnI isoform; or (3) better thin filament
regulation of acto-myosin binding, caused by a higher
density of TnC, resulting in less cross-bridge binding in
the absence of calcium. We see evidence for the second
hypothesis – that these changes to kinetics and Ca2+
sensitivity correlate with the proportion of ssTnI to cTnI
– in both our data and in previous work on animal models
of development. Fetal sheep hearts (Posterino et al. 2011)
and fetal mouse hearts (Siedner et al. 2003) demonstrate
continuous increases in the proportion of cTnI to total
TnI, which has been correlated with decreased Ca2+
sensitivity of contraction (McAuliffe & Robbins, 1991;
Siedner et al. 2003; Krüger et al. 2006; Posterino et al.
2011). Here, we also report an elevated (compared
with previously reported adult) but decreasing calcium
sensitivity as gestational age increases in the human fetal
heart myofibrils. Additionally, similar to studies in other
mammalian models of development, we also observed
a steady increase in the amount of cTnI throughout
gestation. The high proportion of ssTnI in the fetal heart
is probably responsible for the increased Ca2+ sensitivity
of fetal cardiac myofibrils compared with adults, and the
shift from ssTnI to cTnI as the fetal human heart develops
correlates with the loss of Ca2+ sensitivity that was
observed. However, we cannot rule out the contribution
of structural changes, or a change in TnC density may
affect the contractile kinetics throughout development.
Future directions
This study provides an initial report on the contractile
and structural properties of human fetal heart myofibrils.
Future studies should include increasing the number of
fetal heart samples at earlier (<100 days) and later (>116
days) gestation stages to increase the robustness of the
data set shown here. Additionally, while these studies were
limited to the left ventricle, the atria are known to carry
far more α-MHC, which is implicated in several forms
of genetically based congenital heart defects, and would
be an important part of the fetal heart to study in the
future. Currently there is considerable focus on the use of
in vitro cultured cardiomyocytes (Burridge et al. 2015) to
test potential therapeutics (Korte et al. 2011) and model
inherited cardiomyopathies (Eschenhagen et al. 2015).
However, the state of contractile maturity of these in vitro
cultured cardiomyocytes is unknown. Therefore, future
work could compare human-induced pluripotent stem
cell-derived cardiomyocytes (hiPSC-CMs) with human
fetal cardiac samples from both atria and ventricle tissues
to assist in understanding the developmental age range
these cells can attain in culture.
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Limitations
This study was limited by the samples obtained; tissues
samples were small in size, with limited maternal data.
In-depth analysis on structure, proteomics and kinetics
could not be studied with the limited number, quality and
size of the samples obtained for these studies. As outlined
in Table 1, samples were of both sexes, multiple ethnicities
and, moreover, subjected to different conditions during
gestation, which could have had unknown effects on the
kinetics and force production. It is apparent in some
samples, such as the single sample from 134 days vs. the
two at 130 days, that variability between samples was large.
This limited our ability to make definitive conclusions and
rigorously test specific hypotheses regarding changes with
increasing gestational age. While we were limited in our
ability to obtain a similar number of samples at individual
gestational ages, the data are consistent to the point that we
can make some preliminary conclusions, and comparison
over a broad range of ages can be used as a framework for
more in-depth studies in the future.
References
Anderson PA, Malouf NN, Oakeley AE, Pagani ED & Allen PD
(1991). Troponin T isoform expression in humans. A
comparison among normal and failing adult heart, fetal
heart, and adult and fetal skeletal muscle. Circ Res 69,
1226–1233.
Belus A, Piroddi N, Scellini B, Tesi C, Amati GD, Girolami F,
Yacoub M, Cecchi F, Olivotto I & Poggesi C (2008). The
familial hypertrophic cardiomyopathy-associated myosin
mutation R403Q accelerates tension generation and
relaxation of human cardiac myofibrils. J Physiol 586,
3639–3644.
Brenner B & Eisenberg E (1986). Rate of force generation in
muscle: correlation with actomyosin ATPase activity in
solution. Proc Natl Acad Sci USA 83, 3542–3546.
Brooks PA, Khoo NS & Hornberger LK (2014). Systolic and
diastolic function of the fetal single left ventricle. J Am Soc
Echocardiogr 27, 972–977.
Burridge PW, Diecke S, Matsa E, Sharma A, Wu H & Wu JC
(2015). Modeling cardiovascular diseases with
patient-specific human pluripotent stem cell-derived
cardiomyocytes. In Methods in Molecular Biology. Humana
Press. DOI: 10.1007/7651_2015_196.
Clemmens EW, Entezari M, Martyn DA & Regnier M (2005).
Different effects of cardiac versus skeletal muscle regulatory
proteins on in vitro measures of actin filament speed and
force. J Physiol 566, 737–746.
Clemmens EW & Regnier M (2004). Skeletal regulatory
proteins enhance thin filament sliding speed and force by
skeletal HMM. J Musc Res Cell Motil 25, 515–525.
Colomo F, Piroddi N, Poggesi C, te Kronnie G & Tesi C (1997).
Active and passive forces of isolated myofibrils from
cardiac and fast skeletal muscle of the frog. J Physiol 500,
535–548.
Cuda G, Pate E, Cooke R & Sellers JR (1997). In vitro actin
filament sliding velocities produced by mixtures of different
types of myosin. Biophys J 72, 1767–1779.
Elmstedt N, Ferm-Widlund K, Lind B, Brodin L-Å & Westgren
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